News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News How Lp(a) Levels Compare With LDL-C in FH: Some Surprises Michael O'Riordan November 17, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Daily News New on the Scene Nonstatin Drugs: Experts Provide Guidance Caitlin E. Cox August 31, 2022
News Conference News ESC 2022 No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE Shelley Wood August 26, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression Michael O'Riordan August 08, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level Michael O'Riordan May 24, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Daily News Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol Michael O'Riordan March 15, 2022